FP7Reintegration grant2010–2013

NAPE-PLD · Structural and functional insight into the biosynthesis of endogenous lipidic messengers by the N-Acyl Phosphatidylethanolamine Phospholipase D (NAPE-PLD)

FP7 — People (Marie Curie Actions)

Duration
2010-10-01 → 2013-09-30
EU contribution
€75,000
Participants
1
Scheme
MC-IRG

Lines connect the coordinator with its partners.

Results in brief

Structural and functional insight into the biosynthesis of endogenous lipidic messengers by the N-Acyl Phosphatidylethanolamine Phospholipase D (NAPE-PLD)

The endogenous Fatty Acid Ethanolamides (FAEs) are lipid signalling molecules emerging for their capacity to promote essential neurological, cytoprotective, and metabolic actions in mammalians. These molecules appear also coordinating nutrient status with obesity, and ultimately affect lifespan and ageing. Among these molecules, “anandamide” has potent anxiolytic and analgesic actions, and is able to stimulate appetite, addiction, and brain synaptogenesis, similarly to the well-known hyperphagic and neurological effects produced by marijuana and hashish. Other FAEs are involved in the modulation of the time frame between meals and inflammatory processes. However, despite the important roles mediated by the FAEs, little was known about the physiological and pathological stimuli that lead to their production in human, and about the mechanism and regulation of their biogenesis. The project “NAPE-PLD” focused on investigating the structural and molecular basis of the biogenesis of the FAEs, and exploring the possibility of targeting the enzyme that produces these important lipid messengers, named NAPE-PLD, for novel diagnostic and therapeutic perspectives in inflammation, metabolic disorders, and neurodegenerative diseases. The project was supported by a Marie Curie Action Grant [PIRG07-GA-2010-268385] to Dr Paola Magotti, under the supervision of Dr Gianpiero Garau, Project leader of Structural Biophysics at the Department of Drug Discovery of the Istituto Italiano di Tecnologia of Genoa (Italy, www.iit.it). Scientific results have been great and beyond expectation. Initially the researchers investigated the localization and trafficking of human NAPE-PLD in cells, and revealed where the biogenesis of the FAEs occurs. Later, they succeed to crystallize this membrane enzyme and determine its atomic structure at 2.6 Å resolution, taking advantage of the radiation generated by the European Synchrotron Radiation Facility (ESRF) of Grenoble (France), the most powerful source of X-rays in Europe (www.esrf.eu‎). The structure of NAPE-PLD revealed the molecular architecture of this enzyme, a functional protein homodimer having an unusual internal channel. The structure showed also how the enzyme associates to cell membranes, and the chemical details of the molecular mechanism that promotes the biosynthesis of FAEs. Structural analysis and other experiments allowed the researchers to unveil that the activity of NAPE-PLD is modulated by the physiological process of fat digestion in the gut. Hence, the biogenesis of lipid amide signals and their effects on gastrointestinal motility, appetite, mood and anxiety, result directly linked to the fat content of foods (Magotti et al, submitted). The discovery that human endogenous cannabinoids and analogue bioactive molecules are produced upon stimuli of fat foods has important therapeutic perspectives for obesity, anorexia, and other metabolic disorders. For example, it suggests how a high-fat diet might be associated in obese people to addiction-like behavior; how people might modulate stress and anxiety by eating foods that have a right content of fat; or how an infant might be encouraged to drink milk by its content of fat. Finally, the project led to the discovery of first potent molecular modulators of NAPE-PLD activity, which are now being evaluated for possible therapeutic uses as drugs. The impact of the results of the NAPE-PLD project is expected to be simply awesome. Findings have the potential to foster a series of future studies and applications in various fields of nutrition, physiology and medicine, which will be extremely relevant for both the scientific and medical community of the EU, and will have important socio-economic implications. Overall, the project shines a light on how eating behavior in humans is influenced by an appropriate amount of fat in food. For inquiries, please visit: http://www.iit.it/en/people/gianpiero-garau.html

Data: CORDIS, © European Union

Project objective

Imbalances of human major lipid signaling pathways contribute to progression in inflammation, neurodegenerative and metabolic diseases. Among lipidic messengers, the family of bioactive N-Acylethanolamines (NAEs) is agonist at cannabinoid and nuclear α-type peroxisome proliferator-activated receptors. The ability of NAEs and their metabolic enzymes to modulate neurotransmission and a variety of pathophysiological processes, including inflammation, appetite, pain and mood, provides unique chances for drug discovery. Upon stimulation, bioactive NAEs are generated from cell membranes in a two-step pathway, which involves an N-acyltransferase and an N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). NAEs bearing saturated and monounsaturated long acyl chains are significantly decreased in NAPE-PLD(-/-) mice suggesting this enzymes as key regulators of the NAE-mediated signaling potential. Very little is known about the molecular architecture of NAPE-PLD and the specific functional role of its N- and C-terminal domains. If given a chance, I will study domain trafficking in activated cells and to solve the X-ray structure of this membrane-bound protein. I will characterize the thermodynamics and kinetics of enzyme interactions, which are essential in understanding how NAPE-PLD synthesizes NEAs and controls their cellular level. Findings will be used for a rational approach in the design of potent and selective NAPE-PLD ligands, which can be exploited pharmacologically to modulate the level of NAEs in inflammation, pain, and neurodegenerative disorders. These aims are a common goal of cell biology, structural biology, pharmacology, and medicinal chemistry, which could give an invaluable blueprint for the design of selective inhibitors, thus strongly impacting both EU scientific research and EU molecular medicine. The Drug Discovery and Development Unit of the Italian Institute of Technology is a unique working environment for their achievement.

Original text from CORDIS.

Participants

  • FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaCoordinatorItaly

Links

Data: CORDIS, © European Union